Bengaluru-based deep-tech startup Nexstem recently raised $3.5 million in funding, co-led by prominent investors including InfoEdge, Zupee, Smile Group, and duo Nikhil Kamath and Abhijeet Pai from Gruhas. This funding will be a significant move in scaling the innovation product ecosystem of the Bengaluru-based company, expanding the portfolio of IP, accelerating the deployment of cutting-edge biosignal infrastructure through the advance Brain-Computer Interface suite, and more.
PC: www.nexstem.ai
Nexstem is an early forerunner in the development of non-invasive BCI solutions for democratizing access to BCI technology. Founded in 2020 by Siddhanth and Deepansh, the company is focused on equipping researchers, clinicians, and developers with the tools to innovate and explore new frontiers in brain-computer interaction, an area of work bound to transform industries like healthcare, gaming, and assistive technologies.
Nexstem’s flagship product, Instinct BCI suite, makes use of the onboard AI-powered compute module, which is made to analyze multiple biosignals from different parts of the body. Having this ability, direct communication becomes possible between the human brain and any external devices for applications that range from neurorehabilitation to cognitive enhancement.
Nexstem Instinct is a development kit meant to help researchers, academics, and innovators navigate through the many complexities found in the implementation and refinement of proof-of-concept use cases for BCI technology. The kit presents an end-to-end platform for bringing together hardware and software development kits, APIs, and real-time biosignal algorithms into an integrated ecosystem. This integration is quite crucial for the facilitation of both research and development in a field that may present many technical challenges.
The fact that industry leaders have spotted the shine of Nexstem’s technology just adds more colors to its potential impact. In fact, it has attracted a number of organizations, such as Microsoft for Startups, NASSCOM, and VIVATech Paris, which underline the fact that the company holds robust and mighty positions in this technology arena. Such recognitions boost the credibility of Nexstem besides giving an opportunity to network, which could well lead to further collaborations and advancements.
Funds from this round will be useful for Nexstem as it prepares to scale product offerings and enhance capability in the BCI domain. Increasing the portfolio of IPs will, of course, enhance Nexstem’s competitive advantage and spur innovation in its technology, with even more pace in the speed of deployment of biosignal infrastructure.
Owing to this sheer forecasted exponential growth of the global BCI market over the next few years, Nexstem is well placed to capitalize on the trend. The approach taken by the startup to make BCI technology accessible highlights the growing interest in applications involving brain-computer interfaces for both medical treatments and merely playing video games.
The funding event happens at a very opportune time; it catalyzes the confidence investors have in its vision and capabilities. It is an important step toward advancing the future of brain-computer interaction. While the startup continues to innovate and expand its reach, it will definitely play a vital role in shaping the landscape of deep-tech solutions and enhancing the way humans interact with technology.
